Board of Directors
Ms Alison Coutts is currently the Executive Chairman of Memphasys Ltd. She has a Chemical Engineering degree and a Graduate Diploma in Biotechnology from the University of Melbourne and an MBA with distinction from Melbourne Business School.
Ms Coutts has extensive experience across a number of industry sectors and disciplines. This includes international engineering project management with Bechtel Corporation in the UK, USA and New Zealand, strategy consulting with Boston Consulting group, executive search with Egon Zehnder International, investment banking at eG Capital, which she co-founded, technology commercialisation over the past 15 years and executive management, currently with Memphasys Ltd.
She is formerly Chair of CSIRO’s Health Sector Advisory Council and was a co-founder and director of eG Capital, which was a preeminent financial advisory firm in the Australian Life Sciences sector.
She was also the former Chairman of Biolink Associates. Until March 2016 Ms Coutts was a Non-Executive Director of DataDot Ltd .
Whilst at eG Capital (2001-2008) Ms Coutts was responsible for analysing the biotech sector and determining which companies eG Capital would support. She was responsible for a number of IPOs and secondary raisings of client companies, and was the key person promoting eG Capital and its clients to the financial community and to the media.
In 2009, Ms Coutts co-founded Mariposa Healthcare Pty Ltd, a drug development company focussed on COPD with two drugs in phase II development.
In 2010, she co-founded Micro-X Ltd, a company which listed on the ASX in December 2015 for $40 million. Micro-X is producing a novel ultra -small and light X-ray machine using carbon nano tubes.
Mr Goodall is a Non-Executive Director of Memphasys Limited and has served as a Director on the Board since March 2012.
He is also a member of the Company's Audit and Risk and Nomination and Remuneration Committees and has been a respected member of Memphasys' committees since joining the board.
Mr Goodall is the Company's largest shareholder and has been a significant shareholder in Memphasys for many years.
Mr Goodall brings a wealth of business, and commercial experience as well as considered judgement to his role as a Memphasys' Director.
He is an entrepreneur who has successfully established a number of businesses throughout his career in Australia and New Zealand.
Having had extensive experience in Commercial Property Investment, Mr Goodall is currently involved in the management of his substantial commercial property interests in New Zealand.
Mr Goodall also has a rural property in northern NSW.
Mr Mikel (M Com, BSc (Hons), Dip Ed, MAICD), joined the Board as a non-executive Director on the 7th June 2018. He has had extensive experience in the pharmaceutical and medical device industries. Mr Mikel has worked in international sales, business development and at general manager and executive board level for Merck and Co and Searle – Pharmacia. He has also worked internationally, ultimately as an executive Board member for IMS Consulting and Services Japan, AsiaPac and ANZ, developing product and portfolio strategies for pharmaceutical and healthcare client companies.
More recently he has focused on developing small, innovative businesses. He founded and subsequently sold Healthy Sleep Solutions after developing it into a successful business, with Resmed Ltd as a joint venture/shareholder partner. He is also a non-executive director of a number of small companies predominantly involved in developing medical devices and diagnostics.
Shane Hartwig is a Certified Practicing Accountant and Chartered Company Secretary and holds a Bachelor of Business degree, majoring in Accounting and Taxation from Curtin University of Technology in Western Australia and is a founding co-Principal of Peloton Advisory. Mr Hartwig has been involved in the areas of initial public offerings, capital raisings, prospectus and information
memorandum preparation and project management, due diligence reviews, mergers and acquisitions (including public company takeover transactions) and providing general corporate advice.Mr Hartwig has over twenty five years’ experience in the finance industry both nationally and internationally with exposure to both the debt and equity capital markets.